Yes, in line with NICE guidelines on ADHD diagnosis and management, patients receiving ADHD medication require ongoing specialist oversight even when shared care is in place.
Adults will continue to have an annual specialist review to monitor treatment effectiveness, tolerability, and any necessary adjustments.
Children and young people will have bi-annual specialist reviews, in line with best practice guidance, to ensure treatment remains appropriate as they develop.
Any changes to medication, including dose titration or treatment discontinuation, will be managed by a Clinical Partners specialist and clearly communicated to you as the primary prescriber.